Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442169 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
A Phase 2 study of West Nile Fever, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
- 5
- Study locations
NCT00442169: Completed Phase 2 study of West Nile Fever, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT00442169 is a Phase 2 study of West Nile Fever that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 208 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00442169, a Phase 2 study of West Nile Fever, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease. The study is divided into two parts; in the first part, a comparison of 3 dose levels of the vaccine will be made, with an inactive control. In the second part, the optimum dose level chosen after the first part will be given to older volunteers.
Primary Outcome
Seroconversion was defined as a fourfold or greater rise in titer between pre- and post-immunization samples
Conditions Studied
Interventions
- BIOLOGICAL ChimeriVax-WN02 Low Dose
- BIOLOGICAL ChimeriVax-WN02 Medium Dose
- BIOLOGICAL ChimeriVax-WN02 High Dose
- BIOLOGICAL 0.9% Saline solution
Study Locations (5)
Arizona
- HOPE Research Institute - Phoenix
Idaho
- Idaho Infectious Diseases, PLLC - Idaho Falls
Kansas
- PRA International Clinical Pharmacology Center - Lenexa
Missouri
- Bio-Kinetic Clinical Applications, Inc. - Springfield
Virginia
- The Glennan Centre for Geriatrics and Gerontologyy, EVMS - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00442169 record still lists
NCT00442169 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% higher).
The record links to 1 condition, with West Nile Fever appearing as the primary indexed condition, and to 4 interventions - of which ChimeriVax-WN02 Low Dose is the first listed.
NCT00442169 lists 5 locations in 5 states (Arizona, Idaho, Kansas).
Frequently Asked Questions
What is clinical trial NCT00442169 about?
NCT00442169 is a clinical study titled "Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults". The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease. The study is divided into two parts; in the first part, a comparison of 3 dose levels of the vaccine will ...
What is the current status of trial NCT00442169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2005-12. Estimated completion is 2009-04.
What conditions does trial NCT00442169 study?
This clinical trial studies the following conditions: West Nile Fever.
What interventions are being tested in trial NCT00442169?
The interventions under investigation include: ChimeriVax-WN02 Low Dose (BIOLOGICAL), ChimeriVax-WN02 Medium Dose (BIOLOGICAL), ChimeriVax-WN02 High Dose (BIOLOGICAL), 0.9% Saline solution (BIOLOGICAL).
Who is sponsoring clinical trial NCT00442169?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00442169 being conducted?
This trial has 5 study locations across Arizona, Idaho, Kansas, Missouri, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for West Nile Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00442169's enrollment target sits among peer trials
208 294th of 2000 higher than 1,704 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia